225 related articles for article (PubMed ID: 37343141)
1. Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk.
Dobbie LJ; Cuthbertson DJ; Hydes TJ; Alam U; Zhao SS
Eur J Endocrinol; 2023 Jun; 188(6):K33-K37. PubMed ID: 37343141
[TBL] [Abstract][Full Text] [Related]
2. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
Yabiku K
Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
Pradhan R; Yin H; Yu O; Azoulay L
Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study.
Zhao SS; Rajasundaram S; Karhunen V; Alam U; Gill D
Semin Arthritis Rheum; 2022 Oct; 56():152058. PubMed ID: 35839537
[TBL] [Abstract][Full Text] [Related]
6. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
[TBL] [Abstract][Full Text] [Related]
7. Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease.
Chen X; Xu C; Hu K; Yang Y; Zhang YJ; Shi HZ; Gu Q; He SM; Zhang C; Wang DD
Expert Rev Clin Pharmacol; 2023; 16(10):991-998. PubMed ID: 37669251
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
Raj H; Durgia H; Palui R; Kamalanathan S; Selvarajan S; Kar SS; Sahoo J
World J Diabetes; 2019 Feb; 10(2):114-132. PubMed ID: 30788048
[TBL] [Abstract][Full Text] [Related]
9. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
[TBL] [Abstract][Full Text] [Related]
10. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Dougherty JA; Guirguis E; Thornby KA
Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
Bea S; Jeong HE; Filion KB; Yu OH; Cho YM; Lee BH; Chang Y; Byrne CD; Shin JY
JAMA Netw Open; 2023 Dec; 6(12):e2349856. PubMed ID: 38153732
[TBL] [Abstract][Full Text] [Related]
13. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD.
Ala M
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34343274
[TBL] [Abstract][Full Text] [Related]
15. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
Androutsakos T; Nasiri-Ansari N; Bakasis AD; Kyrou I; Efstathopoulos E; Randeva HS; Kassi E
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328527
[TBL] [Abstract][Full Text] [Related]
16. SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review.
Xu R; Lian D; Xie Y; Chen Z; Wang Y; Mu L; Wang Y; Zhang B
Front Biosci (Landmark Ed); 2023 Jul; 28(7):134. PubMed ID: 37525911
[TBL] [Abstract][Full Text] [Related]
17. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.
Wong C; Yaow CYL; Ng CH; Chin YH; Low YF; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2020; 11():609135. PubMed ID: 33643221
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Ohki T; Isogawa A; Toda N; Tagawa K
Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
